Characterization of P-glycoprotein transport and inhibition in vivo

Cancer Research

Volumn 58, Issue 2, 1998, Pages 276-282

  Barbarics, Eva ^a   Kronauge, James F ^a   Cohen, Dalia ^b   Davison, Alan ^c   Jones, Alun G ^a   Croop, James M ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM CHLORIDE TL 201; VALSPODAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER RESISTANCE; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; TRANSPORT KINETICS;

ANIMALS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031984371     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Roninson, I. B. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York: Plenum Publishing Corp., 1991.
2. Childs, S., and Ling, V. The MDR superfamily of genes and its biological implications. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Important Advances in Oncology 1994, pp. 21-36. Philadelphia: J. B. Lippincott Company, 1994.
3. Gottesman, M. M., Pastan, I., and Ambudkar, S. V. P-Glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev., 6: 610-617, 1996.
4. Bosch, I., and Croop, J. M. P-Glycoprotein multidrug resistance and cancer. Biochim. Biophys. Acta, 1288: F37-F54, 1996.
5. Gupta, S., and Tsuruo, T. Multidrug Resistance in Cancer Cells: Molecular, Biochemical, Physiological, and Biological Aspects. New York: John Wiley & Sons, 1996.
6. Ames, G. F-L., Mimura, C. S., Holbrook, S. R., and Shyamala, V. Traffic ATPases: a superfamily of transport proteins operating from Escherichia coli to humans. Adv. Enzymol. Relat. Areas Mol. Biol., 65: 1-47, 1992.
7. Higgins, C. F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol., 8: 67-113, 1992.
8. Fisher, G. A., and Sikic, B. I., eds. Drug resistance in clinical oncology and hematology. Hematol. Oncol. Clin. N. Am., 9: 239-511, 1995.
9. Ford, J. M., and Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42: 155-199, 1990.
10. Piwnica-Worms, D., Chiu, M. L., Budding, M., Kronauge, J. F., Kramer, R. A., and Croop, J. M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res., 53: 977-984, 1993.
11. Piwnica-Worms, D., Rao, V. V., Kronauge, J. F., and Croop, J. M. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry. 34: 12210-12220, 1995.
12. Chen, C. C., Meadows, B., Regis, J., Kalafsky, G., Fojo, T., Carrasquillo, J. A., and Bates, S. E. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m Sestamibi. Clin. Cancer Res., 3: 545-552, 1997.
13. Hassan, I. M., Sahweil, A., Constantinides, C., Mahmoud, A., Nair, M., Omar, Y. T., and Abdel-Dayem, H. M. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin. Nucl. Med., 14: 333-340, 1989.
14. Delmon-Moingeon, L. I., Piwnica-Worms, D., Van den Abbeele, A. D., Holman, B. L., Davison, A., and Jones, A. G. Uptake of the cation hexakis (2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res., 50: 2198-2202, 1990.
15. Caner, B., Kitapçl, M., Unlü, M., Erbengi, G., Çalikoglu, T., Gögüs, T., and Bekdik, C. Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP. J. Nucl. Med., 33: 319-324, 1992.
16. Aktolun, C., Bayhan, H., and Kir, M. Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors. Preliminary results and comparison wilh Tl-201. Clin. Nucl. Med., 17: 171-176, 1992.
17. Van Kriekinge, S., Germano, G., Rosen, G., Gupta, P., Waxman, A. D. Tumor quantitation and monitoring in whole-body planar technetium-99m-Sestamibi imaging. J. Nucl. Med., 38: 356-361, 1997.
18. Khalkhali, I., Cutrone, J., Mena, I., Diggles, L., Venegas, R., Vargas, H., Jackson, B., and Klein, S. Technetium-99m-SestaMIBI scintimammography of breast lesions: clinical and pathological follow-up. J. Nucl. Med., 41: 1784-1789, 1995.
19. Ziegels, P., Nocaudie, M., Huglo, D., Deveaux, M., Detourmignies, L., Wattel, E., and Marchandise, X. Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas. Eur. J. Nucl. Med., 22: 126-131, 1995.
20. Archinal-Mattheis, A., Rzepka, R. W., Watanabe, T., Kokubu, N., Itoh, Y., Combates, N. J., Bair, K. W., and Cohen, D. Analysis of the interactions of SDZ PSC 833 ([3′-keto-Bmt1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol. Res., 7: 603-610, 1995.
21. +. Nucl. Med. Biol., 21: 583-591, 1994.
22. Kassis, A. I., and Adelstein, S. J. A rapid and reproducible method for the separation of cells from radioactive media. J. Nucl. Med., 21: 88-90, 1980.
23. Kaplan, W. D., Takvorian, T., Morris, J. H., Rumbaugh, C. L., Connolly, B. T., and Atkins, H. L. Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. J. Nucl. Med., 28: 47-52, 1987.
24. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
25. Keller, R. P., Altermatt, H. J., Nooter, K., Poschmann, G., Laissue, J. A., Bollinger, P., and Hiestand, P. C. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer, 50: 593-597, 1992.
26. Watanabe, T., Tsuge, H., Oh-Hara, T., Naito, M., and Tsuruo, T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol., 34: 235-241, 1995.
27. Gonzalez, O., Colombo, T., De Fusco, M., Imperatori, L., Zucchetti, M., and D'Incalci, M. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother. Pharmacol., 36: 335-340, 1995.
28. Naito, M., Watanabe, T., Tsuge, H., Koyama, T., Oh-hara, T., and Tsuruo, T. Potentiation of the reversal activity of SDZ PSC833 on multi-drug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16. Int. J. Cancer, 67: 435-440, 1996.
29. Watanabe, T., Naito, M., Oh-hara, T., Itoh, Y., Cohen, D., and Tsuruo, T. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid tumor-bearing mouse models. Jpn. J. Cancer Res., 87: 184-193, 1996.
30. Fisher, G. A., Lum, B. L., Hausdorff, J., and Sikic, B. I. Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer, 32A: 1082-1088, 1996.
31. 99Tcm-Sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl. Med. Commun., 16: 253-257, 1995.
32. Del Vecchio, S., Ciarmiello, A., Potena, M. I., Carriero, M. V., Mainolfi, C., Botti, G., Thomas, R., Cerra, M., D'Aiuto, G., Tsuruo, T., and Salvatore, M. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m Sestamibi scan in untreated breast cancer patients. Eur. J. Nucl. Med., 24: 150-159, 1997.
33. Boesch, D., Gaveriaux, C., Jachez, B., Pourtier-Manzanedo, A., Bollinger, P., and Loor, F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 51: 4226-4233, 1991.
34. Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T., and Bates, S. E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol., 46: 627-638, 1994.
35. Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., Berns, A. J. M., and Borst, P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77: 491-502, 1994.
36. Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., and Borst, P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest., 96: 1698-1705, 1995.
37. van Asperen, J., Schinkel, A. H., Beijnen, J. H., Nooijen, W. J., Borst, P., and van Tellingen, O. Altered pharmacokinetics of vinblastine in Mdrla P-glycoprotein-deficient mice. J. Natl. Cancer Inst., 88: 994-999, 1996.
38. Luker, G. D., Fracasso, P. M., Dobkin, J., Piwnica-Worms, D. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-Sestamibi in vivo. J. Nucl. Med., 38: 369-372, 1997.